Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
miR-205-5p drives endothelial dysfunction and senescence in pulmonary fibrosis
Giuseppe Muscato, Benjamin B. Roos, Sharonda Harris, Xiaoyu Tracy Cai, Gina Civettini, Enrico Sciacca, Ahmed A. Raslan, Alessandra Castaldi, Sharon Elliot, Marilyn K. Glassberg, Carlo Vancheri, Daniel J. Tschumperlin, Giovanni Ligresti, Nunzia Caporarello
Giuseppe Muscato, Benjamin B. Roos, Sharonda Harris, Xiaoyu Tracy Cai, Gina Civettini, Enrico Sciacca, Ahmed A. Raslan, Alessandra Castaldi, Sharon Elliot, Marilyn K. Glassberg, Carlo Vancheri, Daniel J. Tschumperlin, Giovanni Ligresti, Nunzia Caporarello
View: Text | PDF
Research Article Pulmonology Vascular biology

miR-205-5p drives endothelial dysfunction and senescence in pulmonary fibrosis

  • Text
  • PDF
Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal, aging-related disease characterized by persistent lung fibroblast activation, progressive lung scarring, and several vascular abnormalities. We have previously demonstrated that aging-associated vascular dysfunction drives maladaptive endothelial responses to injury and exacerbates lung fibrosis via secretion of profibrotic endothelial cell–derived factors. However, regulatory mechanisms governing endothelial dysfunction during progressive lung fibrosis remain poorly understood. Here, using preclinical mouse models of progressive lung fibrosis as well as human IPF lungs, we demonstrate that miR-205-5p was overexpressed in lung endothelial cells (ECs) from fibrotic lungs and coordinated gene expression programs implicated in endothelial dysfunction and progressive fibrosis. Mechanistically, miR-205-5p induced senescence in lung ECs, mirroring the senescent phenotype of IPF lung ECs. Consistently, conditioned medium derived from lung ECs overexpressing miR-205-5p promoted lung fibroblast activation. Importantly, miR-205-5p inhibition in IPF lung ECs attenuated endothelial senescence and limited paracrine fibroblast activation. Finally, inhibition of miR-205-5p in vivo preserved the pulmonary vascular network and attenuated lung fibrosis progression in aged mice challenged with bleomycin. Collectively, our findings support what we believe to be a novel connection among lung endothelial miR-205-5p, endothelial senescence, and profibrotic alteration of the endothelial secretome and highlight miR-205-5p inhibition as a potential therapeutic intervention for pulmonary fibrosis.

Authors

Giuseppe Muscato, Benjamin B. Roos, Sharonda Harris, Xiaoyu Tracy Cai, Gina Civettini, Enrico Sciacca, Ahmed A. Raslan, Alessandra Castaldi, Sharon Elliot, Marilyn K. Glassberg, Carlo Vancheri, Daniel J. Tschumperlin, Giovanni Ligresti, Nunzia Caporarello

×

Figure 6

miR-205-5p affects endothelial function potentially by targeting the YAP and CDKN1A cascades, and its inhibition in IPF lung ECs partially mitigates their profibrotic phenotype.

Options: View larger image (or click on image) Download as PowerPoint
miR-205-5p affects endothelial function potentially by targeting the YAP...
(A) Schematic depicting our target prediction analysis workflow (created with a licensed version of BioRender.com). (B) Network pathway analysis (IPA) of genes predicted to be targets of miR-205-5p in our study. (C) Selected predicted target genes in YAP and CDKN1A cascades. (D) Predicted miR:target alignment region. Lines indicate Watson-Crick base pairs; dots indicate G:U wobble base pairs. (E–G) qPCR showing changes in miR-205-5p predicted target genes and genes associated to endothelial dysfunction in IPF lung ECs transfected with a miR-205-5p inhibitor. Inhibition of miR-205-5p leads to the upregulation of the predicted target genes YAP1, WWC2, and BRCA1; upregulation of the survival gene BIRC5; and downregulation of profibrotic genes IGF1 and IL1B. The predicted target gene CDK19 remains unchanged. N = 3 independent biological replicates. Data are expressed as mean ± SD, and P values were calculated using Student’s t test. *P < 0.05; **P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts